Joint development of a regenerative medicine product for Fabry disease with セルジェンテック
A theme involving the acquisition, under an agreement with セルジェンテック, of rights including joint development rights for a regenerative medicine product for Fabry disease using genetically modified human adipocytes.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.